CL2022001173A1 - Forma cristalina de la base libre de un receptor del componente c5a del complemento - Google Patents
Forma cristalina de la base libre de un receptor del componente c5a del complementoInfo
- Publication number
- CL2022001173A1 CL2022001173A1 CL2022001173A CL2022001173A CL2022001173A1 CL 2022001173 A1 CL2022001173 A1 CL 2022001173A1 CL 2022001173 A CL2022001173 A CL 2022001173A CL 2022001173 A CL2022001173 A CL 2022001173A CL 2022001173 A1 CL2022001173 A1 CL 2022001173A1
- Authority
- CL
- Chile
- Prior art keywords
- free base
- crystalline form
- receptor
- complement component
- compound
- Prior art date
Links
- 239000012458 free base Substances 0.000 title abstract 3
- 230000000295 complement effect Effects 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932652P | 2019-11-08 | 2019-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001173A1 true CL2022001173A1 (es) | 2023-02-10 |
Family
ID=75846182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001173A CL2022001173A1 (es) | 2019-11-08 | 2022-05-04 | Forma cristalina de la base libre de un receptor del componente c5a del complemento |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11026935B2 (https=) |
| EP (1) | EP4054577A4 (https=) |
| JP (1) | JP2022554019A (https=) |
| KR (1) | KR20220098179A (https=) |
| CN (1) | CN114641289A (https=) |
| AU (1) | AU2020378061A1 (https=) |
| BR (1) | BR112022007488A2 (https=) |
| CA (1) | CA3155596A1 (https=) |
| CL (1) | CL2022001173A1 (https=) |
| IL (1) | IL292317A (https=) |
| MX (1) | MX2022005403A (https=) |
| WO (1) | WO2021092292A1 (https=) |
| ZA (1) | ZA202305622B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| JP2022554019A (ja) * | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| JP7839157B2 (ja) * | 2020-10-28 | 2026-04-01 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996467B2 (ja) * | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| CN114867473A (zh) * | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| JP2022554019A (ja) * | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 JP JP2022525889A patent/JP2022554019A/ja not_active Withdrawn
- 2020-11-06 KR KR1020227018961A patent/KR20220098179A/ko not_active Withdrawn
- 2020-11-06 WO PCT/US2020/059287 patent/WO2021092292A1/en not_active Ceased
- 2020-11-06 MX MX2022005403A patent/MX2022005403A/es unknown
- 2020-11-06 CA CA3155596A patent/CA3155596A1/en active Pending
- 2020-11-06 EP EP20884944.8A patent/EP4054577A4/en not_active Withdrawn
- 2020-11-06 CN CN202080077446.8A patent/CN114641289A/zh active Pending
- 2020-11-06 AU AU2020378061A patent/AU2020378061A1/en not_active Abandoned
- 2020-11-06 IL IL292317A patent/IL292317A/en unknown
- 2020-11-06 BR BR112022007488A patent/BR112022007488A2/pt not_active IP Right Cessation
- 2020-11-06 US US17/091,019 patent/US11026935B2/en active Active
-
2021
- 2021-05-04 US US17/307,865 patent/US20220096453A1/en not_active Abandoned
-
2022
- 2022-05-04 CL CL2022001173A patent/CL2022001173A1/es unknown
-
2023
- 2023-04-24 US US18/305,611 patent/US20230381167A1/en not_active Abandoned
- 2023-05-25 ZA ZA2023/05622A patent/ZA202305622B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021092292A1 (en) | 2021-05-14 |
| US20210137907A1 (en) | 2021-05-13 |
| BR112022007488A2 (pt) | 2022-07-12 |
| EP4054577A1 (en) | 2022-09-14 |
| AU2020378061A1 (en) | 2022-05-26 |
| US20230381167A1 (en) | 2023-11-30 |
| JP2022554019A (ja) | 2022-12-27 |
| IL292317A (en) | 2022-06-01 |
| US11026935B2 (en) | 2021-06-08 |
| EP4054577A4 (en) | 2023-11-29 |
| MX2022005403A (es) | 2022-05-24 |
| US20220096453A1 (en) | 2022-03-31 |
| ZA202305622B (en) | 2024-01-31 |
| CN114641289A (zh) | 2022-06-17 |
| KR20220098179A (ko) | 2022-07-11 |
| CA3155596A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001173A1 (es) | Forma cristalina de la base libre de un receptor del componente c5a del complemento | |
| CL2022001172A1 (es) | Forma amorfa de un receptor del componente c5a del complemento | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| CU20220005A7 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| AR119174A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| CO2022004305A2 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| SA521421354B1 (ar) | مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون | |
| CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
| CL2024001045A1 (es) | Formas de sal de un receptor del componente c5a del complemento | |
| SA521421262B1 (ar) | مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه | |
| MX2022004144A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| ECSP23091202A (es) | Moduladores de trex1 | |
| MX2017007955A (es) | Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. | |
| MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
| CY1125227T1 (el) | Μορφες δοσολογιας που περιλαμβανουν αναστολεα kαλλικρεϊνης πλασματος |